Great Point Partners

Great Point Partners, established in 2003, is a Connecticut-based private equity firm that invests in healthcare companies across the United States, Canada, and Western Europe. The firm focuses on special situation, buyout, and growth equity investments, with a particular interest in pharma infrastructure services, healthcare IT-enabled services, medical devices, and other healthcare sectors. Great Point Partners is known for its long history of supporting executives in building successful healthcare companies, with an investment team augmented by CEO and Medical Advisory Boards. The firm typically invests in companies with EBITDA ranging from $1 to $10 million, and has raised multiple funds, including a $200 million fund in 2006.

James Conte

Analyst

Bill Gallucci

Operating Partner

Alexander Gulotta

Senior Vice President

Edward A. Hjerpe

Senior Vice President

Jeffrey R. Jay

Founder, Managing Director

Harrison Johnson

Senior Associate

Lily Li

Analyst

Lillian Nordahl

Managing Director and Co-Portfolio Manager

John O’Malley

Senior Associate

Joseph Pesce

Managing Director

William Reckmeyer

Analyst

Noah F. Rhodes III

Managing Director

Jessica Rosenstack

Analyst

Rohan Saikia

Managing Director

David Slattery

Senior Vice President

Aaron Spivak

Principal

David Szeto

Senior Analyst

Bret Tenenhaus

Principal

Christopher Weiss

Analyst

Jerry Yang Ph.D

Principal

Tavi Yehudai

Managing Director

Stephen Yenouskas

Senior Associate

Noah Rhodes

Managing Director and Head of Private Equity

59 past transactions

Jade Biosciences

Post in 2025
Jade Biosciences is a biopharmaceutical company dedicated to developing innovative therapies for unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the APRIL pathway for treating IgA nephropathy, with initial clinical trials planned. Additionally, Jade has two preclinical antibody discovery programs, JADE-002 and JADE-003. The company was founded upon assets licensed from Paragon Therapeutics.

Rezolute

Post in 2025
Rezolute Inc., established in 2010 and headquartered in Redwood City, California, is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company's primary product candidate, RZ358, is a human monoclonal antibody currently in Phase 2b trials for treating congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. Additionally, Rezolute is advancing RZ402, a small molecule plasma kallikrein inhibitor in preclinical stages for diabetic macular edema treatment. The company aims to improve existing standards of care by applying proprietary formulation and manufacturing capabilities to known molecules.

Neurogene

Post in 2024
Neurogene Inc., established in 2018 and headquartered in New York, specializes in developing genetic medicines for treating neurological disorders. The company focuses on utilizing adeno-associated virus (AAV) vectors to deliver therapeutic genes for conditions such as Charcot-Marie Tooth disease type 4J (CMT4J), Aspartylglucosaminuria (AGU), and an undisclosed Lysosomal Storage Disease (LSD). Neurogene aims to provide effective treatment options where none currently exist, aiming to improve the quality of life for patients and families affected by these rare neurological disorders.

Inventiva Pharma

Post in 2024
Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Cellipont Bioservices

Venture Round in 2024
Cellipont Bioservices is a contract development and manufacturing organization (CDMO) focused on cell therapy products for biopharmaceutical companies. The company offers a range of services, including cell therapy development and production, from small to large batches. Its expertise encompasses the production of therapeutic proteins and antibodies, as well as cell culture and purification development. Cellipont also provides troubleshooting for existing processes and analytical development support. Additionally, the company offers cell banking and various support services, ensuring that clients receive comprehensive assistance throughout the development and manufacturing stages of their cell therapy products.

Oruka Therapeutics

Post in 2024
Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

ProMIS Neurosciences

Post in 2024
ProMIS Neurosciences, Inc. is a development-stage biotechnology company based in Toronto, Canada, focused on developing precision therapeutic solutions for neurodegenerative diseases, primarily Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). Established in 2004, the company employs a proprietary target discovery engine that integrates thermodynamic and computational techniques to identify disease-specific epitopes on misfolded proteins. Its lead product candidates include PMN310, PMN350, and PMN330, which are monoclonal antibodies targeting toxic forms of amyloid beta oligomers and prion-like proteins associated with AD. Additionally, ProMIS is developing treatments targeting the neurotoxic tau protein in AD and proteins linked to ALS and PD. The company collaborates with BC Neuroimmunology to advance proprietary diagnostic assays and blood-based tests for Alzheimer’s disease, enhancing early detection and treatment efficacy. Formerly known as Amorfix Life Sciences Ltd., ProMIS Neurosciences has rebranded itself to reflect its focus on neurological therapeutics.

Context Therapeutics

Post in 2024
Context Therapeutics LLC is a clinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, focused on developing innovative therapies for hormone-responsive cancers. Founded in 2015, the company’s primary aim is to address female hormone-dependent cancers, including breast, ovarian, and endometrial cancer. Context's lead program is Apristor (Onapristone XR), an investigational drug currently in Phase 2 trials for treating progesterone receptor positive metastatic breast and ovarian cancers. The company is also advancing CTX-030916, a potential oral antiprogestin designed for uterine fibroids and endometriosis. Additionally, Context is engaged in a discovery-stage program targeting Sigma1 and has developed CTIM-76, a bispecific antibody aimed at redirecting T-cell-mediated lysis towards malignant cells expressing CLDN6. Through its focused pipeline, Context Therapeutics is committed to creating effective treatments for patients with solid tumors.

Zura Bio

Post in 2024
Zura Bio is a clinical-stage biotechnology company that develops innovative therapies for immune and inflammatory disorders. The company focuses on advancing its programs through phase 2 development, specifically targeting auto-immune illnesses. One of its key assets, ZB-168, is an anti-IL7R inhibitor designed to address disorders linked to the biological pathways of IL7 and TSLP, building on data from phase 1b studies related to type 1 diabetes. Additionally, Zura Bio is progressing the phase 2 clinical development of torudokimab, a human-affinity monoclonal antibody that neutralizes IL33. Through these efforts, Zura Bio aims to create effective therapeutic solutions for patients suffering from various immune-related conditions.

Unicycive Therapeutics

Post in 2024
Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’s Syndrome and by addressing the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease. Unicycive Therapeutics was founded in 2016 and is headquartered in Los Altos, California.

Lexicon Pharmaceuticals

Post in 2024
Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products to treat various human diseases. The company's portfolio includes several drug candidates in different stages of clinical trials. LX9211 is an orally-delivered small molecule being tested for neuropathic pain treatment. Sotagliflozin, another orally-delivered small molecule, is under investigation for heart failure and type 1 diabetes. Additionally, the company has developed LX4211 for type 2 diabetes, LX2931 for rheumatoid arthritis and other autoimmune diseases, and LX7101 for glaucoma treatment. Lexicon Pharmaceuticals has established collaborations with several pharmaceutical companies, including Bristol-Myers Squibb, Genentech, Organon, Takeda, Symphony Icon, Taconic Farms, and Nuevolution A/S.

MindMed

Post in 2024
MindMed provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC.

Ocular Therapeutix

Post in 2024
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company offers several products, including ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery, and DEXTENZA, an ophthalmic insert for the treatment of post-surgical ocular pain and inflammation, as well as allergic conjunctivitis and dry eye diseases. Ocular Therapeutix is also developing OTX-TP, an insert aimed at reducing intraocular pressure in glaucoma patients, and OTX-TIC, an intracameral implant for similar indications, along with OTX-TKI, an intravitreal implant targeting wet age-related macular degeneration. In addition, the company has preclinical programs focused on various ocular conditions. Ocular Therapeutix collaborates with Regeneron Pharmaceuticals to integrate its hydrogel technology with Regeneron's VEGF-targeting compounds for retinal disease treatments. Founded in 2006, the company is headquartered in Bedford, Massachusetts.

Jasper Therapeutics

Post in 2024
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, focused on developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. The company aims to create safer conditioning agents that enable broader use of curative therapies, particularly through its novel engineered hematopoietic stem cells platform. Its lead compound, JSP191, is a humanized monoclonal antibody currently in clinical development. This agent functions as a conditioning treatment by targeting and clearing hematopoietic stem cells from bone marrow, facilitating successful stem cell transplants. By addressing the limitations of transplant grafts, Jasper Therapeutics seeks to increase the number of patients who can benefit from both allogeneic and autologous gene-edited hematopoietic stem cell therapies.

Outlook Therapeutic

Post in 2024
Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company based in Cranbury, New Jersey, specializing in the development and commercialization of monoclonal antibodies for ophthalmic conditions. The company's primary product candidate, ONS-5010, is a proprietary formulation of bevacizumab currently undergoing Phase-III clinical trials aimed at treating wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion, among other retinal diseases. Outlook Therapeutics has established collaboration and license agreements with several partners, including IPCA Laboratories Limited and Laboratorios Liomont, among others. Originally incorporated in 2010 as Oncobiologics, the company rebranded to its current name in November 2018 to better reflect its focus on ophthalmic therapeutics.

Ludi

Private Equity Round in 2023
Ludi, Inc. is a healthcare technology firm based in Nashville, Tennessee, founded in 2012. The company specializes in providing solutions to help hospitals and health systems automate and manage their administrative processes related to physician payments and agreements. Its flagship product, DocTime Log, is an automated mobile solution that allows physicians to easily log their hours, manage monthly activities, and track financial alignment with healthcare organizations. Ludi's platform integrates complex tasks and data into a single financial management system, enabling healthcare providers to audit payments, improve compliance, optimize revenue, and enhance physician satisfaction. In addition to its technology solutions, Ludi offers consulting services to assist organizations in evaluating their processes and building strong relationships with physician partners.

Arvinas

Post in 2023
Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Tourmaline Bio

Post in 2023
Tourmaline Bio is a clinical biotechnology company focused on developing transformative medicines aimed at improving the lives of patients suffering from immune diseases. The company is in the late stages of clinical development and is centered on its lead product candidate, TOUR006, a fully human monoclonal antibody designed to selectively target interleukin-6 (IL-6), a significant proinflammatory cytokine implicated in various autoimmune and inflammatory disorders. The IL-6 antibody class has a well-established history, with over two decades of clinical and commercial experience, having successfully treated more than a million patients with diverse autoimmune and inflammatory conditions. Through its innovative research, Tourmaline Bio seeks to address the unmet medical needs of patients affected by life-altering immune diseases.

VistaGen Therapeutics

Post in 2023
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders, particularly depressive and social anxiety disorders. The company's lead product candidate, AV-101, is an orally available treatment currently in Phase 2 development for major depressive disorder, targeting patients who have not adequately responded to standard antidepressants. Additionally, VistaGen is advancing PH94B, a neuroactive nasal spray, which is preparing for Phase III clinical trials for the acute treatment of anxiety in adults with social anxiety disorder. Another product in its pipeline, PH10, is being planned for Phase 2b development as a treatment for major depressive disorder. VistaGen has established licensing and collaboration agreements to facilitate the clinical development and commercialization of its products, including a strategic partnership for PH94B in Greater China, South Korea, and Southeast Asia. Founded in 1998, VistaGen is headquartered in South San Francisco, California.

Zura Bio

Post in 2023
Zura Bio is a clinical-stage biotechnology company that develops innovative therapies for immune and inflammatory disorders. The company focuses on advancing its programs through phase 2 development, specifically targeting auto-immune illnesses. One of its key assets, ZB-168, is an anti-IL7R inhibitor designed to address disorders linked to the biological pathways of IL7 and TSLP, building on data from phase 1b studies related to type 1 diabetes. Additionally, Zura Bio is progressing the phase 2 clinical development of torudokimab, a human-affinity monoclonal antibody that neutralizes IL33. Through these efforts, Zura Bio aims to create effective therapeutic solutions for patients suffering from various immune-related conditions.

Abivax

Post in 2023
Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

Immunic Therapeutics

Post in 2022
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

iXCells Biotechnologies

Private Equity Round in 2022
iXCells Biotechnologies specializes in preclinical drug discovery solutions, offering services that focus on disease-relevant cellular models. The company provides cell biology and technology services aimed at assisting the academic, biotech, and pharmaceutical sectors in the development of therapeutic drugs and disease models. By enabling clients with innovative technologies and comprehensive support, iXCells Biotechnologies accelerates the pace of drug discovery, contributing to advancements in the field of medical research.

Ventyx Biosciences

Post in 2022
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.

Heron Therapeutics

Post in 2022
Heron Therapeutics is a biotechnology company dedicated to developing innovative treatments for unmet medical needs, primarily in the area of nausea and pain management. Utilizing its proprietary Biochronomer drug delivery technology, the company provides sustained therapeutic levels of short-acting pharmacological agents with a single administration over several days. Heron's product offerings include SUSTOL, an extended-release injection designed to prevent nausea and vomiting associated with certain chemotherapy regimens, and CINVANTI, an intravenous formulation for managing nausea linked to highly emetogenic chemotherapy. The company is also advancing investigational products such as HTX-011, a dual-acting combination of bupivacaine and meloxicam currently in Phase III trials for pain management, and HTX-034 for postoperative pain. Founded in 1983 and headquartered in San Diego, California, Heron Therapeutics was previously known as A.P. Pharma, Inc. before rebranding in 2014.

Ephicacy

Private Equity Round in 2022
Established in 2005 with headquarters in Jersey City, New Jersey, US, Ephicacy was founded with the singular objective of being a niche provider of consultancy, functional and capability enhancement services in the area of data management, biostatistics and CDISC conversion, supporting research and clinical trials activities of leaders in the life sciences industry. Ephicacy’s presence in Bangalore, India was established in 2009 as a Center of Excellence (COE), stemming from our conviction of the locally available talent pool. Our investments in hiring and nurturing talent through well established learning and development processes have led to the creation of a competent and committed team. The COE in India is highly delivery driven with well established SOPs. Ephicacy also has an ISO 9001 : 2008 Certified quality systems. Ephicacy extended its consultancy and services operations into the European region during early 2011. Our global delivery organization comprises of a well knit team of experienced data managers, programmers, biostatisticians and domain expert based in the US, India and Europe. The India Centre of Excellence complements the capabilities of our presence in the US and Europe. Ephicacy has stepped in to address the paucity of qualified resources in these functional areas and is able to rapidly fulfill the needs of customers using flexible and bespoke business engagement models. Our highly qualified leadership team handpicks from our pool of qualified professionals to ensure customer projects are well resourced. Today, Ephicacy has proven to be pioneer and continues to be a forerunner in providing ACCURATE, RELIABLE and ON TIME solutions for the life sciences industry.

JPA Health

Private Equity Round in 2022
JPA Health is a comprehensive health communication agency that specializes in public relations, marketing, and advocacy. The company offers a range of services, including earned media, patient advocacy relations, public affairs, and stakeholder engagement. In addition to these core services, JPA Health also provides digital and creative solutions such as design, social media marketing, video production, and animation. By combining strategic insights with creative execution, JPA Health assists clients in developing health campaigns that aim to drive change and achieve measurable outcomes.

Cellipont Bioservices

Acquisition in 2022
Cellipont Bioservices is a contract development and manufacturing organization (CDMO) focused on cell therapy products for biopharmaceutical companies. The company offers a range of services, including cell therapy development and production, from small to large batches. Its expertise encompasses the production of therapeutic proteins and antibodies, as well as cell culture and purification development. Cellipont also provides troubleshooting for existing processes and analytical development support. Additionally, the company offers cell banking and various support services, ensuring that clients receive comprehensive assistance throughout the development and manufacturing stages of their cell therapy products.

Velentium

Venture Round in 2021
Velentium is a designer and manufacturer of therapeutic and diagnostic medical devices, catering to clients of various sizes, from startups to established Fortune 500 companies. The company specializes in cybersecurity, device development, test systems, and medical device manufacturing. Velentium offers expertise in software, usability, cybersecurity, as well as electrical and mechanical development for medical equipment. Through these services, the company helps clients transform their intellectual property into safe and secure products that aim to improve lives. Customer inquiries are addressed through multiple channels, including phone, email, and online applications.

BioAtla

Post in 2021
BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

Magenta Therapeutics

Post in 2021
Magenta Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies to enhance stem cell transplantation for patients with blood cancers, genetic diseases, and autoimmune disorders. The company aims to improve the safety and efficacy of stem cell transplants, which are currently high-risk procedures often considered only as a last resort. Its pipeline includes several key product candidates, such as targeted antibody-drug conjugates for transplant conditioning, a novel stem cell mobilization agent, and allogeneic stem cell therapies. Magenta is also exploring collaborations to assess the effectiveness of its therapies in combination with existing treatments, such as gene therapies for sickle cell disease. Founded in 2015 and headquartered in Cambridge, Massachusetts, Magenta Therapeutics seeks to expand the curative potential of stem cell therapies to a broader patient population by addressing the toxicity and long-term side effects associated with current transplant methods.

Silence Therapeutics

Post in 2021
Silence Therapeutics plc is a biotechnology company based in London, specializing in the discovery and development of innovative RNA therapeutics. The company focuses on utilizing short interfering RNA (siRNA) technology to modulate gene expression and address various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. Its pipeline includes several product candidates, such as SLN124, aimed at treating iron overload disorders by silencing the TMPRSS6 gene, and SLN360, which targets the LPA gene to reduce the risk of cardiovascular diseases. Silence Therapeutics has established strategic collaborations with major organizations, including AstraZeneca, to advance the development of siRNA therapeutics across multiple disease areas. The company leverages its proprietary genetic toolkit and delivery systems to optimize therapeutic outcomes, harnessing the body's natural biological mechanisms for effective treatment.

Bionova Scientific

Private Equity Round in 2019
Bionova Scientific, Inc. is a biologics contract development and manufacturing organization based in Fremont, California, founded by a group of biopharmaceutical specialists in 2014. The company specializes in providing comprehensive services for biologics development and manufacturing, including early-stage research material generation, cell line development for new biological entities and biosimilars, and process development. Bionova Scientific supports the production of various biomolecules such as glycoproteins, monoclonal antibodies, and enzymes, focusing on optimizing expression systems and scaling up cell culture processes. Their expertise also extends to technology transfer and ensuring that biologic therapies are efficiently developed and brought to market for drug development companies.

Axiom

Private Equity Round in 2019
Axiom Real-Time Metrics Inc. specializes in developing eClinical software tailored for small to medium-sized life sciences organizations, including biotechnology and pharmaceutical companies. Founded in 2001 and headquartered in Toronto, Canada, the company offers a comprehensive suite of solutions that encompasses electronic data capture, data management, clinical trial management systems, randomization services, and electronic patient-reported outcomes. Axiom’s software is designed to facilitate the operational and data management needs of clients conducting clinical trials, allowing them to streamline their research processes effectively. In addition to its software offerings, Axiom provides services such as biostatistics, pharmacovigilance, and training, ensuring that clients receive comprehensive support throughout their clinical studies.

Nebula Genomics

Series A in 2018
Nebula Genomics is a company that focuses on human genome sequencing and health data, aiming to create a comprehensive online marketplace for genomic information. Founded in 2016 by Harvard genomics pioneer George Church and his colleagues, the company is headquartered in San Francisco, California, with additional offices in Boston, Massachusetts. Nebula Genomics utilizes blockchain technology to empower consumers by allowing them to maintain control over their genomic data and receive compensation for its use. The platform aggregates extensive genetic information, enabling researchers to analyze data for accelerated drug development and personalized medicine. The company’s DNA sequencing technology covers all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, facilitating in-depth genetic analysis and variant exploration.

Clinical Supplies Management

Debt Financing in 2018
Clinical Supplies Management (CSM) specializes in addressing the intricate supply challenges faced by biotech and pharmaceutical companies during clinical trials. The company offers comprehensive clinical trial and biological sample management services, which include packaging, labeling, storage, distribution, and consulting. By utilizing a combination of traditional and innovative approaches, CSM provides customized solutions that enable clients to efficiently manage drug supplies and ancillary materials, even in the face of time constraints and mid-study changes. Their extensive network and proprietary ERP systems facilitate the seamless execution of clinical trials, helping clients in the pharmaceutical, medical testing, biotechnology, and healthcare sectors to conduct efficient and effective studies while minimizing waste and costs.

Aurinia Pharmaceuticals

Post in 2014
Aurinia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company headquartered in Victoria, Canada, focused on developing and commercializing therapies for serious diseases with significant unmet medical needs. The company is primarily engaged in the development of voclosporin, an investigational drug aimed at treating lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia's efforts are concentrated on targeted patient populations in the United States and China, where it seeks to provide innovative solutions for conditions that currently lack effective treatments.

Apyx Medical

Post in 2013
Apyx Medical Corp is a medical device company focused on energy technology, dedicated to developing, manufacturing, and marketing a variety of surgical and cosmetic products. The company is known for its innovative Renuvion cosmetic technology, which enables plastic and cosmetic surgeons to apply controlled heat to tissues, achieving desired aesthetic results with minimal invasiveness. Apyx Medical's flagship J-Plasma system utilizes a patented helium ionization process to generate a stable, focused beam of plasma, allowing for precise cutting, coagulation, and ablation of soft tissue while minimizing unintended damage to surrounding areas. Apyx Medical’s products are utilized in a range of settings, including doctor's offices, surgery centers, and hospitals, highlighting the company's commitment to enhancing surgical outcomes through advanced medical technologies.

Health Revenue Assurance Holdings

Venture Round in 2013
HRAA interprets data to ensure that healthcare is efficient and effective for everyone by pulling medical data together to create a predictive window to understand cost and revenues looking back and going forward. Founded in 2001 and based out of Plantation, FL, HRAA combines years of industry expertise with best-in-breed technology to create market leading business intelligence products and consulting services to ensure hospitals are reimbursed for every pill they prescribe, every procedure they perform and every test they administer. HRAA both trains and supplies the high tech workforce to hospitals to generate the predictive data used by the whole healthcare system and offers a full suite of solutions needed to keep up with the ever-changing healthcare industry including data analytics software, business intelligence technology, medical coding, auditing, education, revenue cycle consulting, and ICD-10 transition solutions.

Ocera Therapeutics

Post in 2013
Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for patients suffering from acute and chronic liver diseases, addressing a significant unmet medical need. The company's lead product, OCR-002, functions as an ammonia scavenger and is being investigated in both intravenous and oral formulations to treat hyperammonemia. Recently, Ocera completed a Phase 2b clinical trial named STOP-HE, which assessed the safety and efficacy of intravenously administered OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. Ocera is currently preparing for a meeting with the FDA to discuss the intravenous program and explore potential development pathways for its therapeutics.

iVantage Health Analytics

Private Equity Round in 2013
iVantage Health Analytics, Inc. specializes in healthcare analytics and business intelligence solutions tailored for the healthcare industry. The company offers a range of products, including the Hospital Strength INDEX, which evaluates U.S. acute-care hospitals based on financial and performance metrics. Its VantagePoints platform delivers population health analytics and consulting services aimed at enhancing clinical performance and optimizing reimbursement. Additionally, iVantage provides tools such as iBenchmarks, which helps hospitals identify operational and clinical improvement opportunities, and the INCONTROL Contract Optimizer, which assesses market dynamics affecting hospital operations. Other offerings include EnvisionHIT for healthcare business planning, iVantage Market Intelligence for strategic insights, and iVantage Performance Manager for cloud-based performance management. Founded in 2006 and headquartered in Portland, Maine, iVantage operates additional offices in several states and has been a subsidiary of The Chartis Group since 2015.

Connecture

Venture Round in 2012
Connecture, Inc. is a web-based platform that specializes in consumer shopping, enrollment, and retention for health insurance distribution in the United States, focusing primarily on the Medicare insurance sector. Founded in 1999 and headquartered in Milwaukee, Wisconsin, the company offers personalized solutions that help users identify suitable health insurance plans based on their individual preferences, health conditions, preferred providers, medications, and anticipated out-of-pocket costs. Connecture serves a diverse clientele, including payers, brokers, government agencies, and online insurance marketplace operators. The company has refined its focus to exclusively cater to the Medicare market, providing tools such as the PlanCompare and DrugCompare product suites through software-as-a-service installations, along with integration, managed hosting, and customer support services. In 2019, Connecture was acquired by Harris Computer Systems, further solidifying its position in the health insurance technology landscape.

Aris Radiology

Private Equity Round in 2011
Aris Radiology provides a range of professional radiology services to healthcare institutions, including hospitals and surgery centers. The company is Joint Commission certified and collaborates with local medical facilities and radiology groups to deliver a comprehensive hybrid solution. Aris offers high-quality radiologists and ensures 24/7 subspecialty coverage and operational support, which enhances the quality of patient care while maintaining cost-effectiveness. Additionally, the company supports its clients with services such as patient billing, radiologist recruitment, and operational business development. This combination of expertise and service helps improve diagnostic accuracy and patient safety across the healthcare system.

WaferGen Biosystems

Post in 2011
WaferGen Bio-systems, Inc. is an emerging genomic analysis company in the early stage of commercialization. The company offers the transformative SmartChip Real-Time PCR System—a next-generation Real-Time PCR System for profiling and validation of gene expression patterns (biomarkers) on a single platform. The SmartChip System provides a range of high-throughput capabilities including microRNA and mRNA gene expression profiling and single nucleotide polymorphism (SNP) genotyping.

Biodel

Post in 2011
Biodel Inc. is a development-stage biopharmaceutical company based in Danbury, Connecticut, focused on creating treatments for diabetes. The company leverages its proprietary VIAdel technology to enhance the formulation of existing drugs, aiming to improve their efficacy and delivery. Biodel's lead product candidate is Linjeta, a rapid-acting mealtime insulin designed for individuals with Type I and Type II diabetes. In addition to Linjeta, the company is exploring earlier-stage candidates that include follow-on and second-generation rapid-acting insulins, a sublingual insulin tablet known as VIAtab, a line of basal insulins, and a glucagon formulation. Through its innovative approach, Biodel aims to address the needs of diabetes patients and improve their treatment options.

American Surgical Professionals

Acquisition in 2011
American Surgical Professionals specializes in providing surgical assistant services to hospitals, clinics, surgeons, and patients. The company offers customized solutions for perioperative staffing needs, which include supplying skilled surgical assistants on an outsourced or contractual basis. By focusing on improving surgical care, American Surgical Professionals manages staff recruitment, scheduling, and training, thereby enabling healthcare providers to enhance patient outcomes and reduce operational costs.

Cytovance Biologics

Venture Round in 2011
Cytovance Biologics, Inc. is a biopharmaceutical contract manufacturing organization based in Oklahoma City, Oklahoma, specializing in the production of therapeutic proteins and antibodies through mammalian cell culture and microbial fermentation. Founded in 2003, the company offers a range of services including cell line selection, process development, purification, and fill/finish operations, all adhering to current Good Manufacturing Practices (cGMP). Additionally, Cytovance provides analytical development, qualification, and regulatory support, as well as project management and quality assurance services. Its state-of-the-art facilities are FDA inspected, enabling the company to serve biopharmaceutical clients in the United States effectively. As of 2015, Cytovance Biologics operates as a subsidiary of Hepalink USA Inc.

Solta Medical

Post in 2010
Solta Medical, Inc. is a medical device company specializing in energy-based systems for aesthetic applications. Founded in 1995 and headquartered in Hayward, California, the company designs, develops, and manufactures a range of products for skin rejuvenation and body contouring. Notable offerings include the Thermage NXT system, which provides non-invasive skin tightening and cellulite enhancement, as well as the Fraxel re:fine, re:store, and re:pair systems, which address various skin conditions such as fine lines, pigmentation, acne scars, and deeper wrinkles. These systems comprise handpieces, a user-friendly console, an energy source, and disposable treatment tips. Solta Medical serves a diverse clientele, including dermatologists, plastic surgeons, and gynecologists, and distributes its products through a direct sales force and a network of distributors both in the United States and internationally. The company was previously known as Thermage, Inc. before rebranding to Solta Medical in January 2009.

BioSante Pharmaceuticals

Post in 2010
BioSante Pharmaceuticals, Inc. (BioSante) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company's products for female sexual health, menopause, contraception and male hypogonadism include LibiGel, a once daily transdermal testosterone gel in Phase III clinical development under a special protocol assessment (SPA) for the treatment of female sexual dysfunction (FSD); Elestrin, a once daily transdermal estradiol (estrogen) gel indicated for the treatment of moderate-to-severe vasomotor symptoms; The Pill-Plus (triple component contraceptive), a once daily use of various combinations of estrogens, progestogens and androgens in development for the treatment of female sexual dysfunction (FSD) in women using oral or transdermal contraceptives, and Bio-T-Gel, a once daily transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency, in men.

Solta Medical

Post in 2010
Solta Medical, Inc. is a medical device company specializing in energy-based systems for aesthetic applications. Founded in 1995 and headquartered in Hayward, California, the company designs, develops, and manufactures a range of products for skin rejuvenation and body contouring. Notable offerings include the Thermage NXT system, which provides non-invasive skin tightening and cellulite enhancement, as well as the Fraxel re:fine, re:store, and re:pair systems, which address various skin conditions such as fine lines, pigmentation, acne scars, and deeper wrinkles. These systems comprise handpieces, a user-friendly console, an energy source, and disposable treatment tips. Solta Medical serves a diverse clientele, including dermatologists, plastic surgeons, and gynecologists, and distributes its products through a direct sales force and a network of distributors both in the United States and internationally. The company was previously known as Thermage, Inc. before rebranding to Solta Medical in January 2009.

Inhibitex

Post in 2009
Inhibitex specializes in the development of antibody-based products aimed at preventing and treating bacterial and fungal infections. The company emphasizes the creation of small molecule antiviral compounds, with a particular focus on therapies for shingles, also known as herpes zoster, and chronic hepatitis C infections.

Threshold Pharmaceuticals

Post in 2009
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

APT Pharmaceuticals

Series B in 2008
APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

Biotronic NeuroNetwork

Private Equity Round in 2008
Biotronic NeuroNetwork specializes in providing neurophysiological intraoperative monitoring services to surgeons and healthcare facilities throughout the United States. The company focuses on enhancing patient safety during surgeries that pose risks to neural structures by delivering real-time monitoring and critical data analysis. With a commitment to quality care, Biotronic partners with over 650 hospitals and monitors more than 45,000 surgeries each year. Utilizing proprietary software and a secure virtual private network, Biotronic ensures reliable and efficient service, enabling surgeons to respond promptly to potential complications. The company's expertise and dedication to clinical research and education further support its mission to improve surgical outcomes while maintaining cost-effective partnerships.

SGX Pharmaceuticals

Venture Round in 2007
As of August 20, 2008, SGX Pharmaceuticals, Inc. was acquired by Eli Lilly & Co. SGX Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of therapeutics for addressing unmet medical needs in oncology. The company's product pipeline includes drug candidates from its FAST drug discovery platform, which uses X-ray crystallography and complementary biophysical and biochemical methods, combined with medicinal and computational chemistry. Its drug development programs target the c-MET receptor tyrosine kinase (MET), an enzyme implicated in an array of cancers; and the BCR-ABL tyrosine kinase enzyme for the treatment of chronic myelogenous leukemia (CML), a bone marrow cancer. Under the MET development program, the company develops SGX523, which is in Phase I clinical development studies for solid tumor indications; and SGX126, a preclinical development product for solid tumors indications. Under the BCR-ABL Development Program, SGX Pharmaceuticals develops SGX393, an oral therapy for the second-line treatment of CML, which is in preclinical development studies. Its drug discovery technologies are also applied to a portfolio of oncology targets, including JAK2, a non-receptor tyrosine kinase involved in cytokine-induced signaling and growth regulation, survival, and differentiation of cells; RAS, a protein that regulates cell growth; and three other tyrosine kinases. The company has a license and collaboration agreement with Novartis Institutes for Biomedical Research, Inc., Cystic Fibrosis Foundation Therapeutics, Inc., National Institutes of Health, and Eli Lilly & Company. SGX Pharmaceuticals, formerly known as Structural GenomiX, Inc., was founded in 1998 and is headquartered in San Diego, California.

APT Pharmaceuticals

Series A in 2007
APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

Caprion

Acquisition in 2007
Caprion Proteomics, Inc. is a clinical research organization based in Montreal, Canada, specializing in proteomics and immune monitoring services for the pharmaceutical and biotechnology sectors. The company provides two primary platforms: ImmuneCarta, which utilizes multiparametric flow cytometry for in-depth analyses of immune responses, and ProteoCarta, which employs gel-free and label-free mass spectrometry to compare protein levels across biological samples for biomarker discovery. Caprion offers a diverse range of services, including cell sorting, functional profiling, biomarker discovery, and various assays, addressing multiple disease areas such as autoimmune, cardiovascular, metabolic, neurology, and infectious diseases. Established in 2000, Caprion is dedicated to advancing precision medicine in drug development through strategic partnerships, including one with Viroclinics-DDL. The company rebranded from Caprion Proteomics GP to its current name in July 2007 and operates as a subsidiary of HistoGeneX NV.

Panacos Pharmaceuticals

Post in 2004
Panacos Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of small-molecule oral drugs targeting human immunodeficiency virus (HIV) and other viral diseases. Founded in 1999 and based in Watertown, Massachusetts, the company employs innovative technologies to identify novel targets in the viral life cycle, particularly in areas such as virus maturation and fusion. Its product pipeline includes advanced programs aimed at inhibiting HIV maturation, representing second- and third-generation therapeutic options.

Forbes Medi-Tech

Series A in 2004
Forbes Medi-Tech Inc. is a life sciences company focused on evidence-based nutritional solutions. A leader in nutraceutical technology, Forbes is a provider of value-added products and cholesterol-lowering ingredients for use in functional foods and dietary supplements. Forbes successfully developed and commercialized its Reducol™ plant sterol blend, which has undergone clinical trials in various matrices and has been shown to lower “LDL” cholesterol levels safely and naturally. Building upon established partnerships with leading retailers and manufacturers across the globe, Forbes helps its customers to develop private label and branded products.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.